Endoscopic Treatment for Ureteric Strictures after Kidney Transplantation

What is it about?

This study evaluated the safety and effectiveness of endoscopic treatments with Allium metal ureteric stent (AMUS) for ureteric strictures after kidney transplantation (KT). The overall success rate of endoscopic treatments was 90% during a follow-up period of 1 year. Surgical complications included haematuria (18%), pain (10%), urinary tract infections (7.4%), and lower urinary tract symptoms (7.4%). The incidences of stent migration, occlusion, and encrustation were 10%, 2.9%, and 1.5%, respectively. The study found endoscopic treatment with AMUS to be safe and effective for ureteric strictures after KT with short-term follow-ups.

Featured Image

Why is it important?

The research is important because it evaluates the safety and effectiveness of a new endoscopic treatment option for ureteric strictures after kidney transplantation. This treatment option is important because it can improve the quality of life and long-term outcomes for patients who have experienced failed traditional ureteroplasty, stent placement, and balloon dilatation. Key Takeaways: 1. The overall success rate of endoscopic treatments for ureteric strictures following KT was 90% during a follow-up period of 1 year. 2. The most common location for ureteric strictures was at the vesico-ureteric junction. 3. The surgical procedure was conducted under general anesthesia, and three different types of endoscopic surgeries were available based on the specific location and severity of the stricture. 4. The follow-up protocol included evaluating creatinine levels, eGFR, and blood urea nitrogen levels, and conducting abdominal CT scans, urine routine tests, blood routine tests, and renal function evaluations every 3 months following the stent insertion. 5. The definition of surgical success was the unobstructed drainage of the AMUS, or in cases where there was AMUS migration, occlusion or encrustation and subsequently removed, there was no worsening of renal hydronephrosis in the patient during the follow-up period.